NCT02935907: APG-115 in Patients With Advanced Solid Tumors or Lymphomas

Breast Cancer Type: HER2+, HR+ & HER2-negative, Triple Negative
Hormone Mutations: ER+, PR+
Other Mutations: 
Breast Cancer Tissue: 
Recruitment Status: Recruiting
Phase 1
Drug Category: Misc Inhibitor

Key Eligibility Criteria:

Gender: All
Age: 18 Years and older (Adult, Senior)
Location of Metastases: 
Additional Notes: 
Exclusions: Patients with unstable untreated symptomatic brain metastases- see trial for details; Patients who have received prior treatment with MDM2 inhibitors

Comments are closed.

Up ↑